{"id":193809,"name":"GLAXOSMITHKLINE","slug":"glaxosmithkline","state":"DC","country":"United States of America","description":"Biotechnology pharmaceutical product discovery and development.","totalSpending":1890000,"filings":33,"yearlySpending":[{"year":2018,"income":240000},{"year":2019,"income":240000},{"year":2020,"income":240000},{"year":2021,"income":240000},{"year":2022,"income":360000},{"year":2023,"income":240000},{"year":2024,"income":240000},{"year":2025,"income":90000}],"issues":[{"code":"HCR","display":"Health Issues"}],"firms":["EAST END GROUP, LLC"],"lobbyists":["MICHAEL WOODY","ANDREW HAWKINS","DAVID MOHLER","KELLY CHILDRESS LANGE"],"govEntities":["Health & Human Services, Dept of (HHS)","HOUSE OF REPRESENTATIVES","SENATE"],"sampleDescriptions":["General health care coverage and reimbursement for prescription drugs; reforms to H.R. 3590, the Patient Protection and Affordable Care Act; regulatory issues related to pandemic influenza and biodefe","General health care coverage and reimbursement for prescription drugs; reforms to the Patient Protection and Affordable Care Act; regulatory issues related to pandemic influenza and biodefense vaccine","General health care coverage and reimbursement for prescription drugs; reforms to the Patient Protection and Affordable Care Act; regulatory issues related to pandemic influenza and biodefense vaccine","General health care coverage and reimbursement for prescription drugs; reforms to the Patient Protection and Affordable Care Act; regulatory issues related to pandemic influenza and biodefense vaccine","General health care coverage and reimbursement for prescription drugs; drug pricing reform; and the Food and Drug Administration legislative and regulatory issues. The re-authorization of the Pandemic"]}